Skip to main content
. 2020 Jul 7;2020(7):CD008946. doi: 10.1002/14651858.CD008946.pub3

Comparison 10. Brentuximab vedotin vs. physician's choice (MTX or bexarotene).

Outcome or subgroup title No. of studies No. of participants Statistical method Effect size
10.1 Complete response 1   Risk Ratio (M‐H, Fixed, 95% CI) Subtotals only
10.2 Objective response rate 1   Risk Ratio (M‐H, Fixed, 95% CI) Subtotals only